These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 160589)

  • 81. Kinetic analysis of various heparin fractions and heparin substitutes in the thrombin inhibition reaction.
    Pletcher CH; Cunningham M; Nelsestuen GL
    Biochim Biophys Acta; 1985 Jan; 838(1):106-13. PubMed ID: 2578296
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The relative molecular mass dependence of the anti-factor Xa properties of heparin.
    Ellis V; Scully MF; Kakkar VV
    Biochem J; 1986 Sep; 238(2):329-33. PubMed ID: 3800942
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The binding of low molecular weight heparin to hemostatic enzymes.
    Jordan RE; Oosta GM; Gardner WT; Rosenberg RD
    J Biol Chem; 1980 Nov; 255(21):10073-80. PubMed ID: 6448845
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Mechanism of potentiation of antithrombin III and heparin cofactor II inhibition by sulfated xylans.
    Carson L; Doctor VM
    Thromb Res; 1990 May; 58(4):367-81. PubMed ID: 1972302
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Inhibitory activities for thrombin and factor Xa of whale heparin: comparative studies on two preparations from different species.
    Ototani N; Yosizawa Z
    Tohoku J Exp Med; 1986 Sep; 150(1):77-82. PubMed ID: 3775773
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Involvement of antithrombin III in anticoagulant effects of sulphated polysaccharides [proceedings].
    Kindness G; Williamson FB; Long WF
    Biochem Soc Trans; 1980 Feb; 8(1):82-3. PubMed ID: 6154613
    [No Abstract]   [Full Text] [Related]  

  • 87. [Inactivation of factor X by plasmin].
    Baskova IP; Mirkamalova EG
    Biokhimiia; 1979 Jul; 44(7):1286-8. PubMed ID: 159077
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effect of dextran sulphates on thrombin activity.
    Suzuki K; Hashimoto S
    J Clin Pathol; 1979 May; 32(5):439-44. PubMed ID: 469001
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Normal human plasma contains a naturally occurring antagonist of activated factor X inhibitor (antithrombin III) activity.
    Yin ET; Salsgiver WJ; Tangen O
    Thromb Res; 1979; 15(3-4):557-61. PubMed ID: 494161
    [No Abstract]   [Full Text] [Related]  

  • 90. [The determination of heparin].
    Aiach M
    Ann Biol Clin (Paris); 1982; 40(6):645-50. PubMed ID: 7165134
    [No Abstract]   [Full Text] [Related]  

  • 91. Contribution of exosite occupancy by heparin to the regulation of coagulation proteases by antithrombin.
    Yang L; Manithody C; Qureshi SH; Rezaie AR
    Thromb Haemost; 2010 Feb; 103(2):277-83. PubMed ID: 20024502
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Low molecular weight heparin-catalyzed inactivation of factor Xa and thrombin by antithrombin III--effect of platelet factor 4.
    Schoen P; Lindhout T; Franssen J; Hemker HC
    Thromb Haemost; 1991 Oct; 66(4):435-41. PubMed ID: 1665594
    [TBL] [Abstract][Full Text] [Related]  

  • 93. In vitro coagulant and amidolytic methods for evaluating the activity of heparin and a low molecular weight derivative (PK 10169).
    Walenga JM; Fareed J; Hoppensteadt DA
    Semin Thromb Hemost; 1985 Jan; 11(1):17-25. PubMed ID: 3883497
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Characterization of assembly, product formation, and heparin dissociation steps in the factor Xa reaction.
    Craig PA; Olson ST; Shore JD
    J Biol Chem; 1989 Apr; 264(10):5452-61. PubMed ID: 2925612
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Sulfated, low-molecular-weight lignins are potent inhibitorsof plasmin, in addition to thrombin and factor Xa: Novel opportunity for controlling complex pathologies.
    Henry BL; Abdel Aziz M; Zhou Q; Desai UR
    Thromb Haemost; 2010 Mar; 103(3):507-15. PubMed ID: 20024500
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Inhibition of fibrinolytic enzymes by thrombin inhibitors.
    Gilboa N; Villannueva GB; Fenton JW
    Enzyme; 1988; 40(2-3):144-8. PubMed ID: 2971531
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The role of surface charge on the accelerating action of heparin on the antithrombin III-inhibited activity of alpha-thrombin.
    Heuck CC; Schiele U; Horn D; Fronda D; Ritz E
    J Biol Chem; 1985 Apr; 260(8):4598-603. PubMed ID: 3988727
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Multiple functional domains of the heparin molecule.
    Oosta GM; Gardner WT; Beeler DL; Rosenberg RD
    Proc Natl Acad Sci U S A; 1981 Feb; 78(2):829-33. PubMed ID: 6940150
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effect of heparin on the inactivation rate of human factor XIa by antithrombin-III.
    Scott CF; Schapira M; Colman RW
    Blood; 1982 Oct; 60(4):940-7. PubMed ID: 7115961
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Heparin-activated antithrombin interacts with the autolysis loop of target coagulation proteases.
    Yang L; Manithody C; Rezaie AR
    Blood; 2004 Sep; 104(6):1753-9. PubMed ID: 15178583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.